Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -57.47% is 108% below its 5-year average of -27.58%, near the low end of its 5-year range (-57.47%–-18.15%).
As of the fiscal period ended Tuesday, June 30, 2026. 54.21% below its 12-month average of -37.26%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -57.47%.
RETURN ON EQUITY (ROE)
-57.47%
RETURN ON EQUITY (ROE) AVG TTM
-37.26%
RETURN ON EQUITY (ROE) AVG 3Y
-33.14%
RETURN ON EQUITY (ROE) AVG 5Y
-27.58%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-54.21%
CURRENT VS 3Y AVG
-73.38%
CURRENT VS 5Y AVG
-108.36%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-36.79%
vs the sector median at left
LENZ Therapeutics, Inc.
Market Cap
$118.83M
Return on Equity (ROE)
-57.47%
TTM Avg
-37.26%
3Y Avg
-33.14%
5Y Avg
-27.58%
Market Cap
$118.59M
Return on Equity (ROE)
-148.56%
TTM Avg
-96.59%
3Y Avg
-83.25%
5Y Avg
-64.44%
Market Cap
$119.84M
Return on Equity (ROE)
-663.38%
TTM Avg
-427.48%
3Y Avg
-294.92%
5Y Avg
-251.31%
Market Cap
$117.76M
Return on Equity (ROE)
-61.33%
TTM Avg
-137.84%
3Y Avg
-101.43%
5Y Avg
-77.25%
Market Cap
$120.41M
Return on Equity (ROE)
-30.12%
TTM Avg
-27.41%
3Y Avg
-24.34%
5Y Avg
-19.85%
Market Cap
$120.58M
Return on Equity (ROE)
-2.13%
TTM Avg
-45.09%
3Y Avg
-61.80%
5Y Avg
-44.27%
Market Cap
$116.76M
Return on Equity (ROE)
-22.45%
TTM Avg
-22.96%
3Y Avg
-17.88%
5Y Avg
-19.06%
Market Cap
$115.67M
Return on Equity (ROE)
N/A
TTM Avg
129.36%
3Y Avg
-24207.46%
5Y Avg
-16163.58%
Market Cap
$122.43M
Return on Equity (ROE)
-5.10%
TTM Avg
-4.24%
3Y Avg
-6.16%
5Y Avg
0.09%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | $118.83M | -57.47% | -37.26% | -33.14% | -27.58% |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $118.59M | -148.56% | -96.59% | -83.25% | -64.44% |
| Cibus, Inc. (CBUS)vs › | $119.84M | -663.38% | -427.48% | -294.92% | -251.31% |
| Spruce Biosciences, Inc. (SPRB)vs › | $117.76M | -61.33% | -137.84% | -101.43% | -77.25% |
| Seer, Inc. (SEER)vs › | $120.41M | -30.12% | -27.41% | -24.34% | -19.85% |
| enGene Holdings Inc. (ENGN)vs › | $120.58M | -2.13% | -45.09% | -61.80% | -44.27% |
| MaxCyte, Inc. (MXCT)vs › | $116.76M | -22.45% | -22.96% | -17.88% | -19.06% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | N/A | 129.36% | -24207.46% | -16163.58% |
| BGM Group Ltd. (BGM)vs › | $122.43M | -5.10% | -4.24% | -6.16% | 0.09% |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $122.66M | -71.83% | -71.89% | -76.88% | -67.88% |
ROE
-57.5%
ROA
-53.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -57.47% |
| 2026-03-31 | -44.22% |
| 2025-12-31 | -28.88% |
| 2025-09-30 | -30.36% |
| 2025-06-30 | -25.39% |
| 2025-03-31 | -24.86% |
| 2024-12-31 | -24.39% |
| 2024-09-30 | -28.25% |
| 2024-06-30 | -36.01% |
| 2024-03-31 | -37.31% |
| 2023-06-30 | -27.44% |
| 2023-03-31 | -26.59% |
| 2022-09-30 | -30.47% |
| 2022-06-30 | -25.51% |
| 2022-03-31 | -21.37% |
| 2021-12-31 | -18.15% |
| 2021-09-30 | -28.83% |
| 2021-06-30 | -27.47% |
| 2021-03-31 | -49.84% |
